Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[EX Q]: Paragraph: UPMC announced its collaboration with Bon Secours Health System on a joint venture to expand the Maryland-based nonprofit's campus in Cork, Ireland. The six-story facility will begin offering radiation therapy for cancer patients beginning in 2019. It will be the second radiation center operated by UPMC in Ireland. UPMC opened its first, the Whitfield Cancer Centre in Waterford, in 2006. That facility was the hospital system's first international cancer center. Bon Secours is Ireland's biggest independent hospital group. They operate hospitals in Cork, Dublin, Galway and Tralee. UPMC also manages a cancer radiation center in Rome, Italy. Claim: UPMC partners to expand cancer care network in Ireland.
[EX A]: The University of Pittsburgh Medical Center is expanding its cancer care network in Ireland by entering a partnership on a new radiation therapy center in the country.

[EX Q]: Paragraph: Sweeping testing for the coronavirus among the entire crew of the Roosevelt has already yielded a curious result: The majority of the positive cases so far are among sailors who are asymptomatic. With so many of the crew symptom-free, it is unclear how many of them had been infected and recovered without anyone realizing they had contracted the virus. Many of these infections could have finished their cycle before testing of the crew began. The extent of the infections aboard the vessel should become more clear with results of the new "outbreak investigation" the Navy announced that will use serology testing developed by the U.S. Centers for Disease Control and Prevention (CDC). The serology tests look for the presence of specific antibodies that are created by the immune system's attack response to the presence of the virus and remain in the blood for a period of time. "We are seeking crew member volunteers," Navy Surgeon General Rear Admiral Bruce Gillingham told reporters. The roughly thousand volunteers who are being sought for testing over the next week or so will also be swabbed again for COVID-19, the respiratory disease caused by the virus, as well as asked to answer a short survey, officials said. The U.S. coronavirus death toll - the highest in the world - surged past 35,000 on Friday. It also claimed the life of a sailor from the Theodore Roosevelt this week. The Navy's testing of the entire 4,800-member crew of the aircraft carrier - which is about 94% complete - was an extraordinary move in a case that already has led to the firing of the ship's captain and the resignation of the Navy's top civilian official. It has also given scientific researchers a case study about how the virus spreads asymptomatically in a confined environment among mostly younger adults. That cohort has been somewhat underrepresented in the epidemiological data so far. As of Friday, some 660 sailors - nearly 14% of the crew - had tested positive for the coronavirus. The Navy has said that about 60% of those positive tests were among sailors who were symptom-free. The Navy said medical staff on the island of Guam, where the ship pulled into port, would take the samples and collect questionnaire results. The actual serology tests will be sent to the CDC in Atlanta for analysis. The data could further shed light on how the coronavirus spreads undetected, which could help inform the U.S. national response to the pandemic and efforts to restart the economy. "We will also be sharing that with the White House task force so that that information can be used for the benefit of the nation," Gillingham said. Claim: U.S. to start antibody testing of sailors on coronavirus-hit aircraft carrier.
[EX A]: The U.S. Navy said on Friday it will conduct antibody testing of sailors aboard the coronavirus-hit aircraft carrier Theodore Roosevelt to determine whether they were exposed to the virus as it spread through the ship.

[EX Q]: Paragraph: For stent patients, use of Lilly and Daiichi Sankyo Co Ltd's prasugrel could offer better protection against heart attack, stroke and death from cardiovascular events than standard treatment with Plavix, researchers said in an article published in the journal Lancet's online edition. The results of the sub-analysis of data from the TRITON-TIMI 38 trial were being presented Saturday at the American College of Cardiology meeting in Chicago. Study investigators found that intensive anti-clotting therapy with prasugrel resulted in fewer serious complications, including stent-related blood clots known as stent thrombosis, than with standard Plavix, regardless of the type of stent used. A 58 percent reduction in stent thrombosis was seen with prasugrel compared with Plavix. "Stent thrombosis was reduced both early and late after stent placement in patients randomly assigned prasugrel," the researchers said. Stents are small wire mesh tubes inserted into the coronary arteries that supply blood to the heart to help keep them from narrowing again after they have been cleared of blockages in an angioplasty procedure. The researchers, led by Stephen Wiviott of Brigham and Women's Hospital and Harvard Medical School, did a sub-analysis of the TRITON-TIMI data to assess the rate, outcomes and prevention of coronary events in 12,844 patients with different types of stents who were treated with prasugrel plus aspirin, or Plavix, also known as clopidogrel, plus aspirin. Roughly half of the patients received bare metal stents and half received stents coated with a drug to prevent re-clogging. Drug-eluting stents reduce the need for repeat procedures but raise the risk of stent thrombosis. Efforts to reduce the risk of stent-related clots, stroke or heart attack have focused on anti-clotting therapy. The original TRITON-TIMI study of heart patients, first unveiled in November, showed prasugrel was 19 percent more effective than Plavix in preventing cardiovascular death, nonfatal heart attacks and strokes, but caused a significantly higher amount of serious bleeding. Plavix, one of the world's best-selling drugs, is sold by Bristol-Myers Squibb Co and Sanofi-Aventis. Lilly in December asked the U.S. Food and Drug Administration to approval prasugrel, considered the most important experimental medicine in its pipeline. If approved, Lilly said the drug's brand name would be Effient. Claim: Lilly drug reduces stent clot risks, study finds.
[EX A]:
Patients who got Eli Lilly and Co's anti-clotting drug prasugrel after a coronary stent procedure had fewer stent-related clots than those on standard drug therapy, an analysis released on Saturday found.